Business
SCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting
Approximately 83% of FURI patients with refractory Candida infections had positive clinical outcomes, defined as complete/partial response (56%) or no disease
About this update from Scynexis, Inc.
[{"type":"text","content":"Approximately 83% of FURI patients with refractory Candida infections had positive clinical outcomes, defined as complete/partial response (56%) or no disease progression (27%). Data from the ongoing Phase 3 CARES study will also be presented demonstrating positive outcomes of ibrexafungerp in 89% of patients with Candida auris, complete/partial response (78%) and no disease progression (11%). JERSEY CITY, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of positive interim data in patients with refractory candidiasis treated with oral ibrexafungerp from the ongoing Phase 3 FURI study, as well as data from the ongoing CARES study of patients with Candida auris (C. auris) infections. The new interim analyses are being presented during the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting being held in Albuquerque, N.M., September 7-9, 2022. “We are pleased to present to the scientific community these interim results from our ongoing FURI and CARES studies showing clinical benefits in patients with serious Candida fungal infections,” said Nkechi Azie, M.D., Vice President, Clinical Development and Medical Affairs at SCYNEXIS. “These encouraging results highlight the potential role of ibrexafungerp in treating a broad spectrum of challenging fungal diseases.” The interim analysis included 64 patients from the FURI study with refractory Candida infections, including failure of or resistance to previous standard-of-care antifungal therapy. In the study, 56% of patients had a complete or partial response, 27% had stable response, 9% showed disease progression, and 8% were indeterminate (including one death due to underlying disease). Among these patients, 71% of refractory vulvovaginal candidiasis (VVC) cases (10/14) treated with an investigational dose regimen of ibrexafungerp showed clinical improvement as determined by vulvovaginal signs and symptoms score ≤1 at test of cure, 7% had stable response, 14% showed disease progression, and 7% were indeterminate. Outcomes for the ongoing Phase 3 CARES study of ibrexafungerp in the treatment of patients with C. auris infections also are being presented at MSGERC. Of the 18 pat...